In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EyeTech: Primary Care Dollars for Specialty Pharma

Executive Summary

Pfizer's $295 million deal for EyeTech's product for macular degeneration is one more example of the Big Pharma's evident belief in the increasing value of specialist, as opposed to primary care, markets. For Pfizer, co-promoting the drug with a start-up is less problematic than most such arrangements because of EyeTech's deep connections with thought leaders in the field and Pfizer's own inexperience in it.
Advertisement

Related Content

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
Corgentech/BMS: Finding Specialty Appeal in a Drug/Device Combo
Corgentech/BMS: Finding Specialty Appeal in a Drug/Device Combo
Biogen Defends its Specialist Market
Biogen Defends its Specialist Market
The Infrastructure Dilemma
The Infrastructure Dilemma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel